REHOVOT, Israel, March 3, 2015 /PRNewswire/ -- At BioHarvest, we believe that nature intentionally provides complex combinations of nutrients to maximize the benefits we receive. Our technology enables the production of safe, scientifically proven, and functional "bio-food" with phytonutrients in their original state, thus, ensuring optimal bioavailability and efficacy.
BioHarvest's flagship product, VINIA™, is a red grape powder that contains a complex of polyphenols (40 mg), including resveratrol (5 mg). BioHarvest sources resveratrol solely from the red grape as piceid (resveratrol glycoside). This is the original form of resveratrol found in red grapes and red wine. Piceid is highly soluble and is stable without the need for preservatives. BioHarvest uses a clean production process - no solvent extraction process is used. Moreover, our product is non-GMO, free from fungicides, pathogens, and pesticides. VINIA™ can be added to existing food and beverage products or consumed directly and provides the benefits of drinking red wine, without the extra sugar, calories, or alcohol.
VINIA™ has gone through ten years of scientific rigor to produce a number of significant pre-clinical and clinical trial studies that uphold its structure-function claims to support heart health, promote healthy blood circulation, and aid anti-oxidant activity. These studies were published in three peer-reviewed scientific journals.
Another study using VINIA™ has recently been completed. The study evaluated the effect of VINIA™ on diabetic parameters as well as clock gene expression. This study involved a group of 33 adults who were given VINIA™ on a daily basis over the course of twelve weeks. Yochi Hagay Ph.D., CEO for BioHarvest commented that, "the preliminary results of this study show that moderate doses of VINIA™ may positively affect patients with Type 2 diabetes. This is a promising result for people with Type 2 diabetes or those at high risk for developing this condition."
The final results of this study will be published in a peer-reviewed journal shortly. "We find the preliminary results from diabetic patients to be extremely encouraging. However, these results still need to be confirmed in a larger patient population," said Malkit Azachi Ph.D. BioHarvest's Vice President of R&D. "We are encouraged by these findings and plan to conduct additional studies to further explore the potential utility of VINIA™ in improving glucose metabolism," concludes Azachi.
About BioHarvest Ltd.
BioHarvest Ltd., is an Israeli biotechnology company founded in 2007 with a mission to develop innovative ingredients that can help people actively take charge of their wellness. By challenging the current health & wellness landscape, BioHarvest leverages science to harness the power of nature and create a new category of super- foods, called "bio-foods," capable of enhancing people's health and overall wellness. To date, BioHarvest is the world's first and only commercial entity to solve the major challenges required to produce biofoods at an industrial scale and harvest these healthy ingredients from nature while maintaining their original chemical structure consistently throughout production. This platform technology is already protected by two U.S. patents.
For more information, please visit http://www.bioharvest.com.
Stuart Cantor, Ph.D.
BioHarvest's Consultant, Scientific Advisory Board
SOURCE BioHarvest Ltd.